Cargando…
Acridine Orange/exosomes increase the delivery and the effectiveness of Acridine Orange in human melanoma cells: A new prototype for theranostics of tumors
Specifically targeted drug delivery systems with low immunogenicity and toxicity are deemed to increase efficacy of cancer chemotherapy. Acridine Orange (AO) is an acidophilic dye with a strong tumoricidal action following excitation with a light source at 466 nm. However, to date the clinical use o...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010124/ https://www.ncbi.nlm.nih.gov/pubmed/28262028 http://dx.doi.org/10.1080/14756366.2017.1292263 |
_version_ | 1783333529800671232 |
---|---|
author | Iessi, Elisabetta Logozzi, Mariantonia Lugini, Luana Azzarito, Tommaso Federici, Cristina Spugnini, Enrico Pierluigi Mizzoni, Davide Di Raimo, Rossella Angelini, Daniela F. Battistini, Luca Cecchetti, Serena Fais, Stefano |
author_facet | Iessi, Elisabetta Logozzi, Mariantonia Lugini, Luana Azzarito, Tommaso Federici, Cristina Spugnini, Enrico Pierluigi Mizzoni, Davide Di Raimo, Rossella Angelini, Daniela F. Battistini, Luca Cecchetti, Serena Fais, Stefano |
author_sort | Iessi, Elisabetta |
collection | PubMed |
description | Specifically targeted drug delivery systems with low immunogenicity and toxicity are deemed to increase efficacy of cancer chemotherapy. Acridine Orange (AO) is an acidophilic dye with a strong tumoricidal action following excitation with a light source at 466 nm. However, to date the clinical use of AO is limited by the potential side effects elicited by systemic administration. The endogenous nanocarrier exosomes have been recently introduced as a natural delivery system for therapeutic molecules. In this article, we show the outcome of the administration to human melanoma cells of AO charged Exosomes (Exo-AO), in both monolayer and spheroid models. The results showed an extended drug delivery time of Exo-AO to melanoma cells as compared to the free AO, improving the cytotoxicity of AO. This study shows that Exo-AO have a great potential for a real exploitation as a new theranostic approach against tumors based on AO delivered through the exosomes. |
format | Online Article Text |
id | pubmed-6010124 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-60101242018-07-11 Acridine Orange/exosomes increase the delivery and the effectiveness of Acridine Orange in human melanoma cells: A new prototype for theranostics of tumors Iessi, Elisabetta Logozzi, Mariantonia Lugini, Luana Azzarito, Tommaso Federici, Cristina Spugnini, Enrico Pierluigi Mizzoni, Davide Di Raimo, Rossella Angelini, Daniela F. Battistini, Luca Cecchetti, Serena Fais, Stefano J Enzyme Inhib Med Chem Research Article Specifically targeted drug delivery systems with low immunogenicity and toxicity are deemed to increase efficacy of cancer chemotherapy. Acridine Orange (AO) is an acidophilic dye with a strong tumoricidal action following excitation with a light source at 466 nm. However, to date the clinical use of AO is limited by the potential side effects elicited by systemic administration. The endogenous nanocarrier exosomes have been recently introduced as a natural delivery system for therapeutic molecules. In this article, we show the outcome of the administration to human melanoma cells of AO charged Exosomes (Exo-AO), in both monolayer and spheroid models. The results showed an extended drug delivery time of Exo-AO to melanoma cells as compared to the free AO, improving the cytotoxicity of AO. This study shows that Exo-AO have a great potential for a real exploitation as a new theranostic approach against tumors based on AO delivered through the exosomes. Taylor & Francis 2017-03-06 /pmc/articles/PMC6010124/ /pubmed/28262028 http://dx.doi.org/10.1080/14756366.2017.1292263 Text en © 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Iessi, Elisabetta Logozzi, Mariantonia Lugini, Luana Azzarito, Tommaso Federici, Cristina Spugnini, Enrico Pierluigi Mizzoni, Davide Di Raimo, Rossella Angelini, Daniela F. Battistini, Luca Cecchetti, Serena Fais, Stefano Acridine Orange/exosomes increase the delivery and the effectiveness of Acridine Orange in human melanoma cells: A new prototype for theranostics of tumors |
title | Acridine Orange/exosomes increase the delivery and the effectiveness of Acridine Orange in human melanoma cells: A new prototype for theranostics of tumors |
title_full | Acridine Orange/exosomes increase the delivery and the effectiveness of Acridine Orange in human melanoma cells: A new prototype for theranostics of tumors |
title_fullStr | Acridine Orange/exosomes increase the delivery and the effectiveness of Acridine Orange in human melanoma cells: A new prototype for theranostics of tumors |
title_full_unstemmed | Acridine Orange/exosomes increase the delivery and the effectiveness of Acridine Orange in human melanoma cells: A new prototype for theranostics of tumors |
title_short | Acridine Orange/exosomes increase the delivery and the effectiveness of Acridine Orange in human melanoma cells: A new prototype for theranostics of tumors |
title_sort | acridine orange/exosomes increase the delivery and the effectiveness of acridine orange in human melanoma cells: a new prototype for theranostics of tumors |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010124/ https://www.ncbi.nlm.nih.gov/pubmed/28262028 http://dx.doi.org/10.1080/14756366.2017.1292263 |
work_keys_str_mv | AT iessielisabetta acridineorangeexosomesincreasethedeliveryandtheeffectivenessofacridineorangeinhumanmelanomacellsanewprototypefortheranosticsoftumors AT logozzimariantonia acridineorangeexosomesincreasethedeliveryandtheeffectivenessofacridineorangeinhumanmelanomacellsanewprototypefortheranosticsoftumors AT luginiluana acridineorangeexosomesincreasethedeliveryandtheeffectivenessofacridineorangeinhumanmelanomacellsanewprototypefortheranosticsoftumors AT azzaritotommaso acridineorangeexosomesincreasethedeliveryandtheeffectivenessofacridineorangeinhumanmelanomacellsanewprototypefortheranosticsoftumors AT federicicristina acridineorangeexosomesincreasethedeliveryandtheeffectivenessofacridineorangeinhumanmelanomacellsanewprototypefortheranosticsoftumors AT spugninienricopierluigi acridineorangeexosomesincreasethedeliveryandtheeffectivenessofacridineorangeinhumanmelanomacellsanewprototypefortheranosticsoftumors AT mizzonidavide acridineorangeexosomesincreasethedeliveryandtheeffectivenessofacridineorangeinhumanmelanomacellsanewprototypefortheranosticsoftumors AT diraimorossella acridineorangeexosomesincreasethedeliveryandtheeffectivenessofacridineorangeinhumanmelanomacellsanewprototypefortheranosticsoftumors AT angelinidanielaf acridineorangeexosomesincreasethedeliveryandtheeffectivenessofacridineorangeinhumanmelanomacellsanewprototypefortheranosticsoftumors AT battistiniluca acridineorangeexosomesincreasethedeliveryandtheeffectivenessofacridineorangeinhumanmelanomacellsanewprototypefortheranosticsoftumors AT cecchettiserena acridineorangeexosomesincreasethedeliveryandtheeffectivenessofacridineorangeinhumanmelanomacellsanewprototypefortheranosticsoftumors AT faisstefano acridineorangeexosomesincreasethedeliveryandtheeffectivenessofacridineorangeinhumanmelanomacellsanewprototypefortheranosticsoftumors |